Evaluation of Adherence, Persistence and Efficacy of Treatment With PCSK9 Inhibitors in Italy

NCT05430828 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 5000

Last updated 2026-01-22

No results posted yet for this study

Summary

Evaluation of adherence, persistence and efficacy of treatment with PCSK9 inhibitors in a real-life Italian population.

Conditions

Interventions

DRUG

Repatha (evolocumab); Praluent (alirocumab)

Dosage form: Injection

Sponsors & Collaborators

  • Federico II University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-07
Primary Completion
2022-01-30
Completion
2030-03-31
FDA Drug
Yes

Countries

  • Italy

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05430828 on ClinicalTrials.gov